89 results on '"Schirmer, Stephan H."'
Search Results
2. Interventional closure vs. medical therapy of patent foramen ovale for secondary prevention of stroke: updated meta-analysis
- Author
-
Vukadinović, Davor, Schirmer, Stephan H., Vukadinović, Aleksandra Nikolovska, Ukena, Christian, Scheller, Bruno, Mahfoud, Felix, and Böhm, Michael
- Published
- 2019
- Full Text
- View/download PDF
3. Kardiovaskuläre Therapie bei chronischer Nierenerkrankung.
- Author
-
Brandenburg, Vincent, Saritas, Turgay, Schirmer, Stephan H., Rogacev, Kyrill, and Heine, Gunnar Henrik
- Subjects
ATRIAL fibrillation ,HEART failure ,HYPERCHOLESTEREMIA ,HYPERTENSION ,ANTICOAGULANTS - Abstract
Copyright of Herz is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
4. Improvement of endothelial function in a murine model of mild cholesterol-induced atherosclerosis by mineralocorticoid antagonism
- Author
-
Kratz, Mario T., Schirmer, Stephan H., Baumhäkel, Magnus, and Böhm, Michael
- Published
- 2016
- Full Text
- View/download PDF
5. Atrial Remodeling Following Catheter-Based Renal Denervation Occurs in a Blood Pressure– and Heart Rate–Independent Manner
- Author
-
Schirmer, Stephan H., Sayed, Marwa M.Y.A., Reil, Jan-Christian, Lavall, Daniel, Ukena, Christian, Linz, Dominik, Mahfoud, Felix, and Böhm, Michael
- Published
- 2015
- Full Text
- View/download PDF
6. Probenecid reduces infection and inflammation in acute Pseudomonas aeruginosa pneumonia
- Author
-
Wonnenberg, Bodo, Tschernig, Thomas, Voss, Meike, Bischoff, Markus, Meier, Carola, Schirmer, Stephan H., Langer, Frank, Bals, Robert, and Beisswenger, Christoph
- Published
- 2014
- Full Text
- View/download PDF
7. Monocyte heterogeneity in human cardiovascular disease
- Author
-
Zawada, Adam M., Rogacev, Kyrill S., Schirmer, Stephan H., Sester, Martina, Böhm, Michael, Fliser, Danilo, and Heine, Gunnar H.
- Published
- 2012
- Full Text
- View/download PDF
8. Inhibition of TRIF-Dependent Inflammation Decelerates Afterload-Induced Myocardial Remodeling.
- Author
-
Bettink, Stephanie I., Reil, Jan-Christian, Kazakov, Andrey, Körbel, Christina, Millenaar, Dominic, Laufs, Ulrich, Scheller, Bruno, Böhm, Michael, and Schirmer, Stephan H.
- Subjects
CARDIAC hypertrophy ,ADAPTOR proteins ,INFLAMMATION ,HEART fibrosis ,TRANSCRIPTION factors ,ALDOSTERONE antagonists - Abstract
Pressure-overload-induced cardiac hypertrophy represents one cause of the development of heart failure. The aim of this study is to characterize the influence of the TIR-domain-containing adapter-inducing interferon-β (TRIF) during afterload-induced myocardial remodeling. After trans-aortic constriction (TAC), cardiac pressure overload leads to an early increase in MyD88- (Myeloid differentiation primary response gene 88) and TRIF-dependent cytokines. The maximum cytokine expression appeared within the first week and decreased to its control level within five weeks. While cardiomyocyte hypertrophy was comparable, the myocardial accumulation of the inflammatory cells was lower in TRIF
−/− mice. At d7, TRIF deficiency reduced transcription factors and TRIF-dependent cytokines. Through the modulation of the TGF-β-signaling pathway and anti-fibrotic microRNAs, TRIF was involved in the development of interstitial fibrosis. The absence of TRIF was associated with a decreased expression of proapoptotic proteins. In echocardiography and working heart analyses, TRIF deficiency slowed left-ventricular wall thickening, myocardial hypertrophy, and reduces the ejection fraction. In summary, TRIF is an important adapter protein for the release of inflammatory cytokines and the accumulation of inflammatory cells in the early stage of maladaptive cardiac remodeling. TRIF is involved in the development of cardiac fibrosis by modulating inflammatory and fibrotic signal transduction pathways. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. Renal nerve ablation
- Author
-
Donazzan, Luca, Mahfoud, Felix, Schirmer, Stephan H, and Böhm, Michael
- Published
- 2015
- Full Text
- View/download PDF
10. Therapeutic Approaches in the Stimulation of the Coronary Collateral Circulation
- Author
-
Degen, Achim, Millenaar, Dominic, and Schirmer, Stephan H.
- Published
- 2014
11. PCSK9-Hemmung – ein Update.
- Author
-
Katzmann, Julius L., Custodis, Florian, Schirmer, Stephan H., and Laufs, Ulrich
- Subjects
LDL cholesterol ,CORONARY artery disease - Abstract
Copyright of Herz is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
12. Plasma biomarkers outperform echocardiographic measurements for cardiovascular risk prediction in kidney transplant recipients: results of the HOME ALONE study.
- Author
-
Emrich, Insa E, Scheuer, Anja L, Rogacev, Kyrill S, Mahfoud, Felix, Wagenpfeil, Stefan, Fliser, Danilo, Schirmer, Stephan H, Böhm, Michael, and Heine, Gunnar H
- Subjects
BRAIN natriuretic factor ,KIDNEY transplantation ,ECHOCARDIOGRAPHY ,CARDIOVASCULAR diseases risk factors ,NATRIURETIC peptides - Abstract
Background Since kidney transplant recipients (KTRs) have a high cardiovascular disease burden, adequate risk prediction is of importance. Whether echocardiographic parameters and plasma biomarkers, natriuretic peptides [N-terminal pro-B-type natriuretic peptide (NT-proBNP)] and troponin T provide complementary or overlapping prognostic information on cardiovascular events remains uncertain. Methods The prospective Heterogeneity of Monocytes and Echocardiography Among Allograft Recipients in Nephrology (HOME ALONE) study followed 177 KTRs for 5.4 ± 1.7 years. Predefined endpoints were hospitalization for acute decompensated heart failure or all-cause death (HF/D) and major atherosclerotic cardiovascular events or all-cause death (MACE/D). At baseline, plasma NT-proBNP, plasma troponin T and echocardiographic parameters [left atrial volume index, left ventricular (LV) mass index, LV ejection fraction, and LV filling pressure] were assessed. Results Among all echocardiographic and plasma biomarkers measured, only NT-proBNP was consistently associated with HF/D in univariate and multivariate {third versus first tertile: hazard ratio [HR] 4.20 [95% confidence interval (CI) 1.02–17.27]} analysis, and only troponin T was consistently associated with MACE/D in univariate and multivariate [third versus first tertile: HR 8.15 (95% CI 2.75–24.18)] analysis. Conclusion Our data suggest that plasma biomarkers are robust and independent predictors of heart failure and atherosclerotic cardiovascular events after kidney transplantation, whereas standard echocardiographic follow-up does not add to risk prediction. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Anti-tumor necrosis factor-[alpha] therapies attenuate adaptive arteriogenesis in the rabbit
- Author
-
Grundmann, Sebastian, Hoefer, Imo, Ulusans, Susann, van Royen, Niels, Schirmer, Stephan H., Ozaki, C. Keith, Bode, Christoph, Piek, Jan J., and Buschmann, Ivo
- Subjects
Tumor necrosis factor -- Research ,Growth factors -- Research ,Biological sciences - Abstract
The specific antagonists of tumor necrosis factor-[alpha] (TNF-[alpha]), infliximab and etanercept, are established therapeutic agents for inflammatory diseases such as rheumatoid arthritis and Crohn's disease. Although the importance of TNF-[alpha] in chronic inflammatory diseases is well established, little is known about its implications in the cardiovascular system. Because proliferation of arteriolar connections toward functional collateral arteries (arteriogenesis) is an inflammatory-like process, we tested in vivo the hypothesis that infliximab and etanercept have antiarteriogenic actions. Sixty-three New Zealand White rabbits underwent femoral artery occlusion and received infliximab, etanercept, or vehicle according to clinical dosage regimes. After 1 wk, collateral conductance, assessed with fluorescent microspheres, revealed significant inhibition of arteriogenesis (collateral conductance): 52.4 (SD 8.1), 35.2 (SD 7.7), and 33.3 (SD 10.1) ml x [min.sup.-1] x 100 [mmHg.sup.-1] with PBS, infliximab, and etanercept, respectively (P < 0.001). High: resolution angiography showed no significant differences in number of collateral arteries, but immunohistochemical analysis demonstrated a decrease in mean collateral diameter, proliferation of vascular smooth muscle cells, and reduction of leukocyte accumulation around collateral arteries in treated groups. Infliximab and etanercept bound to infiltrating leukocytes, which are important mediators of arteriogenesis. Infliximab induced monocyte apoptosis, and neither substance affected monocyte expression of the adhesion molecule Mac-1. We demonstrated that TNF-[alpha] serves as a pivotal modulator of arteriogenesis, which is attenuated by treatment with TNF-[alpha] inhibitors. Reduction of collateral conductance is most likely due to inhibition of perivascular leukocyte infiltration and subsequent lower vascular smooth muscle cell proliferation. This is the first report showing a negative influence of TNF-[alpha] inhibitors on collateral artery growth. collateral circulation; growth factors
- Published
- 2005
14. Margarines supplemented with low dose n-3 fatty acids are not effective in secondary prevention
- Author
-
Laufs, Ulrich and Schirmer, Stephan H.
- Published
- 2012
- Full Text
- View/download PDF
15. Nitric oxide-donating statins: a new concept to boost the lipid-independent effects
- Author
-
Schirmer, Stephan H., Werner, Christian M., Laufs, Ulrich, and Böhm, Michael
- Published
- 2012
- Full Text
- View/download PDF
16. Circulating microparticles as indicators of peripartum cardiomyopathy
- Author
-
Walenta, Katrin, Schwarz, Viktoria, Schirmer, Stephan H., Kindermann, Ingrid, Friedrich, Erik B, Solomayer, Erich Franz, Sliwa, Karen, Labidi, Saida, Hilfiker-Kleiner, Denise, and Böhm, Michael
- Published
- 2012
- Full Text
- View/download PDF
17. Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis
- Author
-
Schirmer, Stephan H., Degen, Achim, Baumhäkel, Magnus, Custodis, Florian, Schuh, Lisa, Kohlhaas, Michael, Friedrich, Erik, Bahlmann, Ferdinand, Kappl, Reinhard, Maack, Christoph, Böhm, Michael, and Laufs, Ulrich
- Published
- 2012
- Full Text
- View/download PDF
18. Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis
- Author
-
van der Laan, Anja M., Schirmer, Stephan H., de Vries, Margreet R., Koning, Jasper J., Volger, Oscar L., Fledderus, Joost O., Bastiaansen, Antonius J.N.M., Hollander, Maurits R., Baggen, Josefien M., Koch, Karel T., Baan, Jan, Jr, Henriques, José P., van der Schaaf, René J., Vis, Marije M., Mebius, Reina E., van der Pouw Kraan, Tineke C., Quax, Paul H., Piek, Jan J., Horrevoets, Anton J., and van Royen, Niels
- Published
- 2012
- Full Text
- View/download PDF
19. Differential effects on inhibition of cholesterol absorption by plant stanol and plant sterol esters in apoE−/− mice
- Author
-
Weingärtner, Oliver, Ulrich, Christof, Lütjohann, Dieter, Ismail, Kenan, Schirmer, Stephan H., Vanmierlo, Tim, Böhm, Michael, and Laufs, Ulrich
- Published
- 2011
- Full Text
- View/download PDF
20. Leptin Augments Cerebral Hemodynamic Reserve after Three-Vessel Occlusion: Distinct Effects on Cerebrovascular Tone and Proliferation in a Nonlethal Model of Hypoperfused Rat Brain
- Author
-
Busch, Hans-Joerg, Schirmer, Stephan H, Jost, Marco, van Stijn, Sylvia, Peters, Stephan L M, Piek, Jan J, Bode, Christoph, Buschmann, Ivo R, and Mies, Guenter
- Published
- 2011
- Full Text
- View/download PDF
21. Gender differences in heart failure: paving the way towards personalized medicine?
- Author
-
Schirmer, Stephan H., Hohl, Mathias, and Böhm, Michael
- Published
- 2010
- Full Text
- View/download PDF
22. Leukocyte subpopulations and arteriogenesis: Specific role of monocytes, lymphocytes and granulocytes
- Author
-
Hoefer, Imo E., Grundmann, Sebastian, van Royen, Niels, Voskuil, Michiel, Schirmer, Stephan H., Ulusans, Susann, Bode, Christoph, Buschmann, Ivo R., and Piek, Jan J.
- Published
- 2005
- Full Text
- View/download PDF
23. Stimulation of collateral artery growth: a potential treatment for peripheral artery disease
- Author
-
Schirmer, Stephan H and van Royen, Niels
- Published
- 2004
- Full Text
- View/download PDF
24. Antikoagulation bei chronisch nierenkranken Menschen mit Vorhofflimmern: Neue Antikoagulanzien (NOAK), Phenprocoumon oder Verzicht auf Antikoagulation?
- Author
-
Schirmer, Stephan H. and Brandenburg, Vincent
- Published
- 2021
- Full Text
- View/download PDF
25. Expression of a retinoic acid signature in circulating CD34 cells from coronary artery disease patients
- Author
-
van der Laan Anja M, Leyen Thomas A, Baggen Josefien M, Moerland Perry D, Fledderus Joost O, Schirmer Stephan H, van der Pouw Kraan Tineke CTM, Piek Jan J, van Royen Niels, and Horrevoets Anton JG
- Subjects
Biotechnology ,TP248.13-248.65 ,Genetics ,QH426-470 - Abstract
Abstract Background Circulating CD34+ progenitor cells have the potential to differentiate into a variety of cells, including endothelial cells. Knowledge is still scarce about the transcriptional programs used by CD34+ cells from peripheral blood, and how these are affected in coronary artery disease (CAD) patients. Results We performed a whole genome transcriptome analysis of CD34+ cells, CD4+ T cells, CD14+ monocytes, and macrophages from 12 patients with CAD and 11 matched controls. CD34+ cells, compared to other mononuclear cells from the same individuals, showed high levels of KRAB box transcription factors, known to be involved in gene silencing. This correlated with high expression levels in CD34+ cells for the progenitor markers HOXA5 and HOXA9, which are known to control expression of KRAB factor genes. The comparison of expression profiles of CD34+ cells from CAD patients and controls revealed a less naïve phenotype in patients' CD34+ cells, with increased expression of genes from the Mitogen Activated Kinase network and a lowered expression of a panel of histone genes, reaching levels comparable to that in more differentiated circulating cells. Furthermore, we observed a reduced expression of several genes involved in CXCR4-signaling and migration to SDF1/CXCL12. Conclusions The altered gene expression profile of CD34+ cells in CAD patients was related to activation/differentiation by a retinoic acid-induced differentiation program. These results suggest that circulating CD34+ cells in CAD patients are programmed by retinoic acid, leading to a reduced capacity to migrate to ischemic tissues.
- Published
- 2010
- Full Text
- View/download PDF
26. SARS-CoV-2-Impfungen – Was muss der Nephrologe wissen?
- Author
-
Heine, Gunnar H., Becker, Sören L., Scheuer, Anja L., and Schirmer, Stephan H.
- Published
- 2021
- Full Text
- View/download PDF
27. Antikoagulation und Thrombozytenaggregationshemmung bei chronischer Nierenkrankheit.
- Author
-
Schirmer, Stephan H., Brandenburg, Vincent, and Antlanger, Marlies
- Published
- 2019
- Full Text
- View/download PDF
28. Echocardiographic criteria to detect unicuspid aortic valve morphology.
- Author
-
Ewen, Sebastian, Karliova, Irem, Weber, Petra, Schirmer, Stephan H, Abdul-Khaliq, Hashim, Schöpe, Jakob, Mahfoud, Felix, and Schäfers, Hans-Joachim
- Subjects
AORTIC stenosis ,MITRAL valve surgery ,TRICUSPID valve surgery ,AORTIC valve abnormalities ,AORTIC valve ,CONFIDENCE intervals ,ECHOCARDIOGRAPHY ,PREOPERATIVE care ,COMORBIDITY ,BODY mass index ,ANATOMY ,DIAGNOSIS - Abstract
Aims Unicuspid aortic valve (UAV) is a rare congenital malformation associated with severe aortic stenosis or regurgitation. This study aimed to systematically determine echocardiographic criteria to identify UAV. Methods and results All patients underwent a preoperative baseline examination, including echocardiography. A total of 69 patients with intraoperatively confirmed UAV underwent an aortic valve repair procedure between August 2001 and May 2011. To compare the findings of UAV cases with those of other valve morphologies, we examined 99 consecutive patients with a bicuspid aortic valve (BAV) and 103 consecutive patients with a tricuspid aortic valve (TAV) undergoing isolated aortic valve surgery before May 2016. The mean age of the 271 patients was 44.2 ± 12.8 years; 85% were male, with a mean body mass index of 26.2 ± 4.0 kg/m
2 . Patients with UAV were younger and had fewer co-morbidities than patients with BAV or TAV, respectively. The major criteria for the echocardiographic diagnosis of UAV were defined based on our preoperative examination as follows: (i) single commissural attachment zone, (ii) rounded, leaflet-free edge on the opposite side of the commissural attachment zone, (iii) eccentric valvular orifice during systole, and (iv) patient age <20 years and mean transvalvular gradient >15 mmHg. The minor criteria were defined as an associated thoracic aortopathy and age <40 years. Three out of the four major criteria or two out of the four major criteria and one minor criterion were met in all patients with UAV and in none of the patients with BAV or TAV. Associated 95% confidence intervals were calculated for each estimate of sensitivity (94.7–100%) and specificity (98.1–100%), indicating that an adequate number of patients were included in each of the three groups. Conclusion The proposed echocardiographic score appears to be a specific and sensitive method to distinguish UAV from BAV and TAV. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
29. Mitral valve interventions in heart failure.
- Author
-
Lavall, Daniel, Hagendorff, Andreas, Schirmer, Stephan H., Böhm, Michael, Borger, Michael A., and Laufs, Ulrich
- Abstract
Abstract: Secondary mitral regurgitation (MR) results from left ventricular dilatation and dysfunction. Quantification of secondary MR is challenging because of the underlying myocardial disease. Clinical and echocardiographic evaluation requires a multi‐parametric approach. Severe secondary MR occurs in up to one‐fourth of patients with heart failure with reduced ejection fraction, which is associated with a mortality rate of 40% to 50% in 3 years. Percutaneous edge‐to‐edge mitral valve repair (MitraClip) has emerged as an alternative to surgical valve repair to improve symptoms, functional capacity, heart failure hospitalizations, and cardiac haemodynamics. Further new transcatheter strategies addressing MR are evolving. The Carillion, Cardioband, and Mitralign devices were designed to reduce the annulus dilatation, which is a frequent and important determinant of secondary MR. Several transcatheter mitral valve replacement systems (Tendyne, CardiAQ‐Edwards, Neovasc, Tiara, Intrepid, Caisson, HighLife, MValve System, and NCSI NaviGate Mitral) are emerging because valve replacement might be more durable compared with valve repair. In small studies, these interventional therapies demonstrated feasibility and efficiency to reduce MR and to improve heart failure symptoms. However, neither transcatheter nor surgical mitral valve repair or replacement has been proven to impact on the prognosis of heart failure patients with severe MR, which remains high with a mortality rate of 14–20% at 1 year. To date, the primary indication for treatment of secondary severe MR is the amelioration of symptoms, reinforcing the value of a Heart Team discussion. Randomized studies to investigate the treatment effect and long‐term outcome for any transcatheter or surgical mitral valve intervention compared with optimized medical treatment are urgently needed and underway. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
30. Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation: The Use of Non-Vitamin K-Dependent Anticoagulants and Vitamin K Antagonists.
- Author
-
Heine, Gunnar H., Brandenburg, Vincent, and Schirmer, Stephan H.
- Abstract
Background: Cardiological societies recommend, in their guidelines, that patients with atrial fibrillation and an intermediate (or higher) risk of stroke and systemic embolization should be treated with oral anticoagulant drugs. For patients who do not have mitral valve stenosis or a mechanical valve prosthesis, non-vitamin-K dependent oral anticoagulants (NOAC) are preferred over vitamin K antagonists (VKA) for this purpose. It is unclear, however, whether patients with chronic kidney disease and atrial fibrillation benefit from oral anticoagulation to the same extent as those with normal kidney function. It is also unclear which of the two types of anti - coagulant drug is preferable for patients with chronic kidney disease; NOAC are, in part, renally eliminated. Methods: This review is based on pertinent publications retrieved by a selective literature search, and on international guidelines. Results: Current evidence suggests that patients with atrial fibrillation who have chronic kidney disease with a glomerular filtration rate (GFR) above 15 mL/ min/1.73 m² should be treated with an oral anticoagulant drug if they have an at least intermediate risk of embolization, as assessed with the CHA
2 DS2 -VASc score. For patients with advanced chronic kidney disease (GFR from 15 to 29 mL/ min/1.73 m²), however, this recommendation is based only on registry studies. For dialysis patients with atrial fibrillation, decisions whether to give oral anticoagulant drugs should be taken on an individual basis, in view of the elevated risk of hemorrhage and the unclear efficacy of such drugs in these patients. The subgroup analyses of the NOAC approval studies show that, for patients with atrial fibrillation and chronic kidney disease with a creatinine clearance of >25-30 mL/min, NOAC should be given in preference to VKA, as long as the patient does not have mitral valve stenosis or a mechanical valve prosthesis. For those whose creatinine clearance is less than 25 mL/min, the relative merits of NOAC versus VKA are still debated. Conclusion: The cardiological societies' recommendation that patients with atrial fibrillation should be given oral anticoagulant drugs applies to the majority of such patients who also have chronic kidney disease. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
31. Modulation of the sympathetic nervous system by renal denervation prevents reduction of aortic distensibility in atherosclerosis prone ApoE-deficient rats.
- Author
-
Hohl, Mathias, Linz, Dominik, Fries, Peter, Müller, Andreas, Stroeder, Jonas, Urban, Daniel, Speer, Thimoteus, Geisel, Jürgen, Hummel, Björn, Laufs, Ulrich, Schirmer, Stephan H., Böhm, Michael, and Mahfoud, Felix
- Subjects
SYMPATHETIC nervous system ,AORTIC diseases ,CATHETERS ,APOLIPOPROTEIN E ,HYPERCHOLESTEREMIA diagnosis ,CARDIOVASCULAR disease related mortality ,ANIMAL models of atherosclerosis ,ENZYME-linked immunosorbent assay ,PREVENTION ,KIDNEY innervation ,ANIMAL experimentation ,ANIMALS ,AORTA ,APOLIPOPROTEINS ,ATHEROSCLEROSIS ,BLOOD pressure ,VASODILATION ,BODY weight ,DENERVATION ,ENDOTHELIUM ,HEART function tests ,INFLAMMATION ,KIDNEYS ,NITROGLYCERIN ,NORADRENALINE ,PARASYMPATHOMIMETIC agents ,RATS ,RENIN-angiotensin system ,FIBROSIS ,DISEASE progression ,IN vitro studies ,PHARMACODYNAMICS - Abstract
Background: Apolipoprotein E-deficient (ApoE(-/-)) rodents spontaneously develop severe hypercholesterolemia and increased aortic stiffness, both accepted risk factors for cardiovascular morbidity and mortality in humans. In patients with resistant hypertension renal denervation (RDN) may improve arterial stiffness, however the underlying mechanisms are incompletely understood. This study investigates the impact of RDN on aortic compliance in a novel atherosclerosis prone ApoE(-/-)-rat model.Methods: Normotensive, 8 weeks old ApoE(-/-) and Sprague-Dawley (SD) rats were subjected to bilateral surgical RDN (n = 6 per group) or sham operation (n = 5 per group) and fed with normal chow for 8 weeks. Compliance of the ascending aorta was assessed by magnetic resonance imaging. Vasomotor function was measured by aortic ring tension recordings. Aortic collagen content was quantified histologically and plasma aldosterone levels were measured by enzyme-linked immunosorbent assay (ELISA).Results: After 8 weeks, ApoE(-/-)-sham demonstrated a 58 % decrease in aortic distensibility when compared with SD-sham (0.0051 ± 0.0011 vs. 0.0126 ± 0.0023 1/mmHg; p = 0.02). This was accompanied by an impaired endothelium-dependent relaxation of aortic rings and an increase in aortic medial fibrosis (17.87 ± 1.4 vs. 12.27 ± 1.1 %; p = 0.006). In ApoE(-/-)-rats, RDN prevented the reduction of aortic distensibility (0.0128 ± 0.002 vs. 0.0051 ± 0.0011 1/mmHg; p = 0.01), attenuated endothelial dysfunction, and decreased aortic medial collagen content (12.71 ± 1.3 vs. 17.87 ± 1.4 %; p = 0.01) as well as plasma aldosterone levels (136.33 ± 6.6 vs. 75.52 ± 8.4 pg/ml; p = 0.0003). Cardiac function and metabolic parameters such as hypercholesterolemia were not influenced by RDN.Conclusion: ApoE(-/-)-rats spontaneously develop impaired vascular compliance. RDN improves aortic distensibility and attenuated endothelial dysfunction in ApoE(-/-)-rats. This was associated with a reduction in aortic fibrosis formation, and plasma aldosterone levels. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
32. Circulating MicroRNAs Characterizing Patients with Insufficient Coronary Collateral Artery Function.
- Author
-
Hakimzadeh, Nazanin, Nossent, A. Yaël, van der Laan, Anja M., Schirmer, Stephan H., de Ronde, Maurice W. J., Pinto-Sietsma, Sara-Joan, van Royen, Niels, Quax, Paul H. A., Hoefer, Imo E., and Piek, Jan J.
- Subjects
MICRORNA ,CORONARY artery bypass ,CORONARY disease ,MYOCARDIAL infarction ,TARGETED drug delivery - Abstract
Background: Coronary collateral arteries function as natural bypasses in the event of coronary obstruction. The degree of collateral network development significantly impacts the outcome of patients after an acute myocardial infarction (AMI). MicroRNAs (miRNAs, miRs) have arisen as biomarkers to identify heterogeneous patients, as well as new therapeutic targets in cardiovascular disease. We sought to identify miRNAs that are differentially expressed in chronic total occlusion (CTO) patients with well or poorly developed collateral arteries. Methods and Results: Forty-one CTO patients undergoing coronary angiography and invasive assessment of their coronary collateralization were dichotomized based on their collateral flow index (CFI). After miRNA profiling was conducted on aortic plasma, four miRNAs were selected for validation by real-time quantitative reverse transcription polymerase chain reaction in patients with low (CFI<0.39) and high (CFI>0.39) collateral artery capacity. We confirmed significantly elevated levels of miR423-5p (p<0.05), miR10b (p<0.05), miR30d (p<0.05) and miR126 (p<0.001) in patients with insufficient collateral network development. We further demonstrated that each of these miRNAs could serve as circulating biomarkers to discriminate patients with low collateral capacity (p<0.01 for each miRNA). We also determined significantly greater expression of miR30d (p<0.05) and miR126 (p<0.001) in CTO patients relative to healthy controls. Conclusion: The present study identifies differentially expressed miRNAs in patients with high versus low coronary collateral capacity. We have shown that these miRNAs can function as circulating biomarkers to discriminate between patients with insufficient or sufficient collateralization. This is the first study to identify miRNAs linked to coronary collateral vessel function in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
33. Exercise Promotes Collateral Artery Growth Mediated by Monocytic Nitric Oxide.
- Author
-
Schirmer, Stephan H., Millenaar, Dominic N., Werner, Christian, Schuh, Lisa, Degen, Achim, Bettink, Stephanie I., Lipp, Peter, van Rooijen, Nico, Meyer, Tim, Böhm, Michael, and Laufs, Ulrich
- Published
- 2015
- Full Text
- View/download PDF
34. Effect of Obstructive Respiratory Events on Blood Pressure and Renal Perfusion in a Pig Model for Sleep Apnea.
- Author
-
Linz, Dominik, Mahfoud, Felix, Linz, Benedikt, Hohl, Mathias, Schirmer, Stephan H., Wirth, Klaus J., and Böhm, Michael
- Subjects
SLEEP apnea syndromes ,CHRONIC kidney failure ,CHRONIC diseases ,KIDNEY failure ,RENAL anemia - Abstract
BACKGROUND Obstructive sleep apnea (OSA) is associated with hypertension and the progression of chronic kidney disease (CKD). Renal sympathetic innervation contributes to either condition. METHODS We investigated the effect of renal sympathetic denervation (RDN) on blood pressure (BP), renal perfusion, and neurohumoral responses during and after repetitive obstructive apneas in a pig model for OSA. BP, femoral artery, and renal artery flow were measured in 29 spontaneously breathing urethane-chloralose–anesthetized pigs. The effect of RDN (n = 14) and irbesartan (n = 3) was investigated. Repetitive tracheal occlusions for 2 minutes with applied negative tracheal pressure at −80 mbar were performed over 4 hours. RESULTS Spontaneous breathing attempts during tracheal occlusion caused an intra-apneic breathing synchronous oscillating pattern of renal flow. Renal flow oscillations were >2-fold higher compared with femoral flow that almost showed changes proportional to the BP alterations (2.9%/mm Hg vs. 1.3%/mm Hg; P < 0.0001). A marked postapneic BP rise from 102±3 to 172±8 mm Hg (P < 0.00001) was associated with renal hypoperfusion (from 190±24 to 70±20ml/min; P < 0.00001) occurring after application of obstructive respiratory events. RDN, but not irbesartan, inhibited postapneic BP rises and renal hypoperfusion and attenuated increased plasma renin activity and aldosterone concentration induced by repetitive tracheal occlusions. Additionally, increased urinary protein/creatinine ratio was significantly reduced by RDN, whereas intra-apneic hemodynamic changes or blood gases were not modified by RDN. CONCLUSIONS Repetitive obstructive respiratory events result in postapneic BP rises and renal hypoperfusion, as well as neurohumoral responses and increased protein/creatinine ratio. These changes are mainly sympathetically driven because they could be attenuated by RDN. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
35. Improvements in Left Ventricular Hypertrophy and Diastolic Function Following Renal Denervation: Effects Beyond Blood Pressure and Heart Rate Reduction.
- Author
-
Schirmer, Stephan H., Sayed, Marwa M.Y.A., Reil, Jan-Christian, Ukena, Christian, Linz, Dominik, Kindermann, Michael, Laufs, Ulrich, Mahfoud, Felix, and Böhm, Michael
- Subjects
- *
HYPERTROPHY , *DIASTOLE (Cardiac cycle) , *KIDNEY surgery , *DENERVATION , *BLOOD pressure , *HEART beat , *LEFT heart ventricle , *HYPERTENSION - Abstract
Objectives: This study sought to investigate the interaction between blood pressure (BP) and heart rate (HR) reduction and changes in left ventricular (LV) structure and function following renal sympathetic denervation (RDN). Background: Hypertension results in structural and functional cardiac changes. RDN reduces BP, HR, and LV mass and improves diastolic dysfunction. Methods: We evaluated LV size, mass, and function before and 6 months after RDN in 66 patients with resistant hypertension and analyzed results in relation to systolic BP (SBP) and HR. Results: SBP decreased by 11 ± 3 mm Hg in the first, 18 ± 5 mm Hg in the second, and 36 ± 7 mm Hg in the third tertile of SBP at baseline (p < 0.001). HR decreased by 13 ± 4 beats/min, 8 ± 3 beats/min, and 11 ± 6 beats/min in tertiles of SBP (p for interaction between tertiles = 0.314). In all SBP tertiles, LV mass index (LVMI) decreased similarly (LVMI −6.3 ± 2.2 g/m2.7, −8.3 ± 2.1 g/m2.7, and −9.6 ± 1.9 g/m2.7; p for interaction = 0.639). LVMI decreased unrelated to HR at baseline (p for interaction = 0.471). The diastolic parameters E-wave deceleration time, isovolumetric relaxation time, and E′-wave velocity improved similarly in all tertiles of SBP and HR. Changes in LV mass and function were also unrelated to reduction in SBP or HR. Vascular compliance improved dependently on BP but independently of HR reduction. Conclusions: In patients with resistant hypertension, LV hypertrophy and diastolic function improved 6 months after RDN, without significant relation to SBP and HR. These findings suggest a direct effect of altered sympathetic activity in addition to unloading on cardiac hypertrophy and function. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
36. Chemokine CCL9 Is Upregulated Early in Chronic Kidney Disease and Counteracts Kidney Inflammation and Fibrosis.
- Author
-
Hemmers, Christian, Schulte, Corinna, Wollenhaupt, Julia, Wong, Dickson W. L., Harlacher, Eva, Orth-Alampour, Setareh, Klinkhammer, Barbara Mara, Schirmer, Stephan H., Böhm, Michael, Marx, Nikolaus, Speer, Thimoteus, Boor, Peter, Jankowski, Joachim, and Noels, Heidi
- Subjects
RENAL fibrosis ,CHRONIC kidney failure ,KIDNEY diseases ,ENZYME-linked immunosorbent assay ,MYELOID cells - Abstract
Inflammation and fibrosis play an important pathophysiological role in chronic kidney disease (CKD), with pro-inflammatory mediators and leukocytes promoting organ damage with subsequent fibrosis. Since chemokines are the main regulators of leukocyte chemotaxis and tissue inflammation, we performed systemic chemokine profiling in early CKD in mice. This revealed (C-C motif) ligands 6 and 9 (CCL6 and CCL9) as the most upregulated chemokines, with significantly higher levels of both chemokines in blood (CCL6: 3–4 fold; CCL9: 3–5 fold) as well as kidney as confirmed by Enzyme-linked Immunosorbent Assay (ELISA) in two additional CKD models. Chemokine treatment in a mouse model of early adenine-induced CKD almost completely abolished the CKD-induced infiltration of macrophages and myeloid cells in the kidney without impact on circulating leukocyte numbers. The other way around, especially CCL9-blockade aggravated monocyte and macrophage accumulation in kidney during CKD development, without impact on the ratio of M1-to-M2 macrophages. In parallel, CCL9-blockade raised serum creatinine and urea levels as readouts of kidney dysfunction. It also exacerbated CKD-induced expression of collagen (3.2-fold) and the pro-inflammatory chemokines CCL2 (1.8-fold) and CCL3 (2.1-fold) in kidney. Altogether, this study reveals for the first time that chemokines CCL6 and CCL9 are upregulated early in experimental CKD, with CCL9-blockade during CKD initiation enhancing kidney inflammation and fibrosis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
37. The collateral circulation of the heart.
- Author
-
Meier, Pascal, Schirmer, Stephan H., Lansky, Alexandra J., Timmis, Adam, Pitt, Bertram, and Seiler, Christian
- Subjects
- *
COLLATERAL circulation , *GRANULOCYTE colony stimulating factor receptor , *CORONARY disease , *HEART physiology , *DONOR blood supply , *MYOCARDIUM physiology - Abstract
The coronary arteries have been regarded as end arteries for decades. However, there are functionally relevant anastomotic vessels, known as collateral arteries, which interconnect epicardial coronary arteries. These vessels provide an alternative source of blood supply to the myocardium in cases of occlusive coronary artery disease. The relevance of these collateral arteries is a matter of ongoing debate, but increasing evidence indicates a relevant protective role in patients with coronary artery disease. The collateral circulation can be assessed by different methods; the gold standard involves intracoronary pressure measurements. While the first clinical trials to therapeutically induce growth of collateral arteries have been unavailing, recent pilot studies using external counterpulsation or growth factors such as granulocyte colony stimulating factor (G-CSF) have shown promising results. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
38. Effects of omega-3 fatty acids on postprandial triglycerides and monocyte activation
- Author
-
Schirmer, Stephan H., Werner, Christian M., Binder, Stephan B.G., Faas, Maria E., Custodis, Florian, Böhm, Michael, and Laufs, Ulrich
- Subjects
- *
OMEGA-3 fatty acids , *TRIGLYCERIDES , *MONOCYTES , *CARDIOVASCULAR disease treatment , *PLACEBOS , *CHEMOKINES , *CIRCADIAN rhythms - Abstract
Abstract: Objective: Epidemiologic studies suggest that elevated postprandial triglycerides (ppTG) are associated with future cardiovascular events. Monocyte activation plays an important role in vascular diseases. Omega-3 fatty acids (n3-FA) lower fasting TG levels. The effects of n3-FA on ppTG and the role of ppTG for monocyte activation are insufficiently understood. Methods and results: 23 healthy volunteers and 30 non-diabetic patients with documented coronary artery disease were subjected to an oral TG tolerance test (OTTT) consisting of 80 g cream fat or to water as control (H2O). Patients were treated with 4 g n3-FA/day or placebo for 3 weeks in a randomized, placebo-controlled, double-blind, crossover study. Relative postprandial TG increase reached its maximum 4 h after fat intake (185.1 ± 10.9% of baseline). n3-FA reduced fasting TG from 137.1 ± 12.9 to 112.2 ± 8.6 mg/dl (p < 0.05), and maximum ppTG concentrations from 243.6 ± 24.6 to 205.8 ± 17.1 mg/dl (p < 0.05), while relative TG increase (192.8 ± 12.7%) was comparable to placebo. Relative monocytopenia and neutrophilia were detected following fat intake, which was unaffected by n3-FA and also detectable in the H2O group. Serum chemotactic cytokine (MCP1 and fractalkine) concentrations and monocyte migration were not affected by fat intake or n3-FA. Monocyte activation markers CD11b and CD14, monocyte subpopulations CD16+CD14high and CD16+CD14low, sICAM serum levels and markers of oxidative stress remained unchanged by fat intake or n3-FA. Conclusion: The postprandial TG increase does not stimulate monocytes beyond their circadian activation patterns. n3-FA reduce fasting TG and the postprandial TG increase. n3-FA may therefore allow to prospectively study whether selected patients benefit from TG-lowering independent of LDL- and HDL-cholesterol. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
39. Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: Current Clinical Evidence and Future Developments
- Author
-
Schirmer, Stephan H., Baumhäkel, Magnus, Neuberger, Hans-Ruprecht, Hohnloser, Stefan H., van Gelder, Isabelle C., Lip, Gregory Y.H., and Böhm, Michael
- Subjects
- *
ANTICOAGULANTS , *CEREBROVASCULAR disease prevention , *ATRIAL fibrillation , *ASPIRIN , *VITAMIN K , *DRUG efficacy , *ANTITHROMBINS - Abstract
Atrial fibrillation (AF) is the most common cardiac rhythm disorder and a major risk factor for ischemic stroke. Antithrombotic therapy using aspirin or vitamin K antagonists (VKA) is currently prescribed for prevention for ischemic stroke in patients with AF. A narrow therapeutic range and the need of regular monitoring of its anticoagulatory effect impair effectiveness and safety of VKA, causing a need for alternative anticoagulant drugs. Recently developed anticoagulants include direct thrombin antagonists such as dabigatran or factor Xa inhibitors such as rivaroxaban, apixaban, betrixaban, and edoxaban. Currently, data from a phase III clinical trial are available for dabigatran only, which show the direct thrombin antagonist to be at least noninferior in efficacy to VKA for the prevention of stroke and systemic embolism in patients with AF. This review focuses on current advances in the development of directly acting oral anticoagulant drugs and their potential to replace the VKA class of drugs in patients with AF. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
40. Vascular Pathophysiology in Response to Increased Heart Rate
- Author
-
Custodis, Florian, Schirmer, Stephan H., Baumhäkel, Magnus, Heusch, Gerd, Böhm, Michael, and Laufs, Ulrich
- Subjects
- *
CARDIOVASCULAR diseases , *PATIENTS , *PATHOLOGICAL physiology , *HEART beat , *HYPERTENSION , *MYOCARDIAL infarction , *ATHEROSCLEROSIS , *LITERATURE reviews ,CARDIOVASCULAR disease related mortality - Abstract
This review summarizes the current literature and the open questions regarding the physiology and pathophysiology of the mechanical effects of heart rate on the vessel wall and the associated molecular signaling that may have implications for patient care. Epidemiological evidence shows that resting heart rate is associated with cardiovascular morbidity and mortality in the general population and in patients with cardiovascular disease. As a consequence, increased resting heart rate has emerged as an independent risk factor both in primary prevention and in patients with hypertension, coronary artery disease, and myocardial infarction. Experimental and clinical data suggest that sustained elevation of heart rate—independent of the underlying trigger—contributes to the pathogenesis of vascular disease. In animal studies, accelerated heart rate is associated with cellular signaling events leading to vascular oxidative stress, endothelial dysfunction, and acceleration of atherogenesis. The underlying mechanisms are only partially understood and appear to involve alterations of mechanic properties such as reduction of vascular compliance. Clinical studies reported a positive correlation between increased resting heart rate and circulating markers of inflammation. In patients with coronary heart disease, increased resting heart rate may influence the clinical course of atherosclerotic disease by facilitation of plaque disruption and progression of coronary atherosclerosis. While a benefit of pharmacological or interventional heart rate reduction on different vascular outcomes was observed in experimental studies, prospective clinical data are limited, and prospective evidence determining whether modulation of heart rate can reduce cardiovascular events in different patient populations is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
41. Blocking Interferon β Stimulates Vascular Smooth Muscle Cell Proliferation and Arteriogenesis.
- Author
-
Schirmer, Stephan H., Bot, Pieter T., Fledderus, Joost O., van der Laan, A. M., Volger, Oscar L., Laufs, Ulrich, Böhm, Michael, de Vries, Carlie J. M., Horrevoets, Anton J. G., Piek, Jan J., Hoefer, Imo E., and van Royen, Niels
- Subjects
- *
CELL proliferation , *CELL cycle , *MUSCLE cells , *APOPTOSIS , *VASCULAR smooth muscle , *INTERFERONS , *LABORATORY mice - Abstract
Increased interferon (IFN)-β signaling in patients with insufficient coronary collateralization and an inhibitory effect of IFNβ on collateral artery growth in mice have been reported. The mechanisms of IFNβ-induced inhibition of arteriogenesis are unknown. In stimulated monocytes from patients with chronic total coronary artery occlusion and decreased arteriogenic response, whole genome expression analysis showed increased expression of IFNβ-regulated genes. Immunohistochemically, the IFNβ receptor was localized in the vascular media of murine collateral arteries. Treatment of vascular smooth muscle cells (VSMC) with IFNβ resulted in an attenuated proliferation, cell-cycle arrest, and increased expression of cyclin-dependent kinase inhibitor-1A (p21). The growth inhibitory effect of IFNβ was attenuated by inhibition of p21 by RNA interference. IFNβ-treated THP1 monocytes showed enhanced apoptosis. Subsequently, we tested if collateral artery growth can be stimulated by inhibition of IFNβ-signaling. RNA interference of the IFNβ receptor-1 (IFNAR1) increased VSMC proliferation, cell cycle progression, and reduced p21 gene expression. IFNβ signaling and FAS and TRAIL expression were attenuated in monocytes from IFNAR1-/- mice, indicating reduced monocyte apoptosis. Hindlimb perfusion restoration 1 week after femoral artery ligation was improved in IFNAR1-/- mice compared with wild-type mice as assessed by infusion of fluorescent microspheres. These results demonstrate that IFNβ inhibits collateral artery growth and VSMC proliferation through p21-dependent cell cycle arrest and induction of monocyte apoptosis. Inhibition of IFNβ stimulates VSMC proliferation and collateral artery growth. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
42. Expression of a retinoic acid signature in circulatingCD34 cells from coronary artery disease patients.
- Author
-
van der Pouw Kraan, Tineke C. T. M., Schirmer, Stephan H., Fledderus, Joost O., Moerland, Perry D., Baggen, Josefien M., Leyen, Thomas A., van der Laan, Anja M., Piek, Jan J., van Royen, Niels, and Horrevoets, Anton J. G.
- Subjects
GENE expression ,TRETINOIN ,CORONARY disease ,CARDIAC patients ,GENES - Abstract
Background: Circulating CD34+ progenitor cells have the potential to differentiate into a variety of cells, including endothelial cells. Knowledge is still scarce about the transcriptional programs used by CD34+ cells from peripheral blood, and how these are affected in coronary artery disease (CAD) patients. Results: We performed a whole genome transcriptome analysis of CD34+ cells, CD4+ T cells, CD14+ monocytes, and macrophages from 12 patients with CAD and 11 matched controls. CD34+ cells, compared to other mononuclear cells from the same individuals, showed high levels of KRAB box transcription factors, known to be involved in gene silencing. This correlated with high expression levels in CD34+ cells for the progenitor markers HOXA5 and HOXA9, which are known to control expression of KRAB factor genes. The comparison of expression profiles of CD34+ cells from CAD patients and controls revealed a less naïve phenotype in patients' CD34+ cells, with increased expression of genes from the Mitogen Activated Kinase network and a lowered expression of a panel of histone genes, reaching levels comparable to that in more differentiated circulating cells. Furthermore, we observed a reduced expression of several genes involved in CXCR4-signaling and migration to SDF1/CXCL12. Conclusions: The altered gene expression profile of CD34+ cells in CAD patients was related to activation/ differentiation by a retinoic acid-induced differentiation program. These results suggest that circulating CD34+ cells in CAD patients are programmed by retinoic acid, leading to a reduced capacity to migrate to ischemic tissues. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
43. Endothelial glycocalyx dimensions are reduced in growing collateral arteries and modulate leucocyte adhesion in arteriogenesis.
- Author
-
Grundmann, Sebastian, Schirmer, Stephan H., Hekking, Liesbeth H. P., Post, Jan Andries, Ionita, Mihaela G., de Groot, Daphne, Royen, Niels van, Berg, Bernard van den, Vink, Hans, Moser, Martin, Bode, Christoph, Kleijn, Dominique de, Pasterkamp, Gerard, Piek, Jan J., and Hoefer, Imo E.
- Subjects
VASCULAR smooth muscle ,FEMORAL artery ,KILLER cells ,LEUCOCYTES ,IMMUNOREGULATION - Abstract
During collateral artery growth, monocytes adhere to the endothelium and secrete cytokines from the perivascular space promoting arteriogenesis. Recently, the endothelial glycocalyx has been shown to modulate leucocyte infiltration in atherogenic regions. The role of this endothelial surface coating in arteriogenesis, however, has not been investigated so far. We now report that local plasma levels of hyaluronic acid are specifically increased in collateral arterial blood of coronary artery disease patients and hypothesized that components of the endothelial glycocalyx are shed during arteriogenesis, resulting in decreased glycocalyx dimensions and an increased leucocyte extravasation. In a rabbit model of femoral artery ligation, electron microscopy revealed a decrease in glycocalyx dimensions in collateral arteries compared with quiescent anastomoses (67.5 ± 47.2 nm versus 101.0 ± 11.3 nm; P < 0.001). This decrease was correlated with a higher number of perivascular macrophages around collateral arteries. The additional glycocalyx perturbation by local hyaluronidase infusion almost completely removed the endothelial surface layer and temporarily stimulated leucocyte accumulation in the perivascular space. However, complete perturbation of the glycocalyx by hyaluronidase infusion resulted in a significant attenuation of collateral artery growth assessed by microsphere-based perfusion measurements (ml/min/100 mmHg: hyaluronidase: 27.5 ± 3.5; Controls: 47.1 ± 3.83; P < 0.001) and a lower percentage of actively proliferating vascular smooth muscle cells. A decreased expression of the shear-stress regulated pro-arteriogenic genes eNOS and TGF-β1 suggests an impaired mechanotransduction as the underlying mechanisms. For the first time, we describe the role of the endothelial glycocalyx in collateral artery growth. Although complete abrogation led to attenuated arteriogenesis, shedding of glycocalyx components is observed during collateral artery growth. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
44. Local Cytokine Concentrations and Oxygen Pressure Are Related to Maturation of the Collateral Circulation in Humans
- Author
-
Schirmer, Stephan H., van Royen, Niels, Moerland, Perry D., Fledderus, Joost O., Henriques, José P., van der Schaaf, René J., Vis, Marije M., Baan, Jan, Koch, Karel T., Horrevoets, Anton J.G., Hoefer, Imo E., and Piek, Jan J.
- Subjects
- *
CYTOKINES , *OXYGEN in the body , *BODY fluid pressure , *MATURATION (Psychology) , *COLLATERAL circulation , *CORONARY disease , *HUMAN biology - Abstract
Objectives: Our aim was to determine cytokine and oxygen gradients over the collateral circulation in humans. Background: The molecular background of the maturation of the collateral circulation in response to coronary narrowing is poorly understood in humans, partly because of difficulties in obtaining local samples from the human collateral circulation. Methods: Coronary collateral blood was sampled in 60 patients with nontotal (n = 25) or total coronary occlusions (n = 35) using a special wide-lumen catheter. Coronary collateral flow index (CFI) was assessed by intracoronary pressure measurements. Oxygenation and lactate content was measured as well as 30 cytokines potentially involved in collateral artery growth, using a custom-made multiplex assay. Results: No rise in lactate or change in pH was found in collateral blood. Oxygen gradient between coronary and collateral arterial blood correlated inversely with CFI (r = −0.61, p < 0.001). Locally increased plasma levels were found for basic fibroblast growth factor, eotaxin, macrophage migration inflammatory factor, monocyte chemoattractant protein-1, and transforming growth factor-beta, while stem cell factor and stem cell growth factor-beta were significantly decreased. The highest cytokine gradients were found in patients with the least developed collateral circulation. The majority of cytokines correlated more strongly with the pO2 gradient across the collateral bed than with CFI. Conclusions: Intravascular ischemia during brief balloon coronary occlusion is absent in human coronary collateral arteries. The oxygen gradient found over the collateral circulation is increased in patients with a less matured collateral circulation and relates to local levels of several known pro-arteriogenic cytokines. In case of a more developed collateral circulation, relatively low levels of cytokines are present, suggesting that growth factor therapy might be beneficial at this stage. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
45. Suppression of inflammatory signaling in monocytes from patients with coronary artery disease
- Author
-
Schirmer, Stephan H., Fledderus, Joost O., van der Laan, Anja M., van der Pouw-Kraan, Tineke C.T.M., Moerland, Perry D., Volger, Oscar L., Baggen, Josefien M., Böhm, Michael, Piek, Jan J., Horrevoets, Anton J.G., and van Royen, Niels
- Subjects
- *
CELLULAR signal transduction , *MONOCYTES , *CORONARY disease , *GENE expression , *ATHEROSCLEROSIS , *PATHOLOGICAL physiology , *BIOMARKERS , *PATIENTS - Abstract
Abstract: Monocytes and T-cells play an important role in the development of atherosclerotic coronary artery disease (CAD). Transcriptome analysis of circulating mononuclear cells from carefully matched atherosclerotic and control patients will potentially provide insights into the pathophysiology of atherosclerosis and supply biomarkers for diagnostic purposes. From patients undergoing coronary angiography because of anginal symptoms, we carefully matched 18 patients with severe triple-vessel CAD to 13 control patients without angiographic signs of CAD. All patients were on statin and aspirin treatment. Elevated soluble-ICAM levels demonstrated increased vascular inflammation in atherosclerotic patients. RNA from circulating CD4+ T-cells, CD14+ monocytes, lipopolysaccharide-stimulated monocytes, and macrophages was subjected to genome-wide expression analysis. In CD14+ monocytes, few inflammatory genes were overexpressed in control patients, while atherosclerotic patients showed overexpression of a group of Krüppel-associated box - containing transcription factors involved in negative regulation of gene expression. These differences disappeared upon LPS-stimulation or differentiation towards macrophages. No consistent changes in T cell transcriptomes were detected. Large inter-individual variability prevented the use of single differentially expressed genes as biomarkers, while monocyte gene expression signature predicted patient status with an accuracy of 84%. In this comprehensive analysis of circulating cell transcriptomes in atherosclerotic CAD, cautious patient matching revealed only small differences in transcriptional activity in different mononuclear cell types. Only an indication of a negative feedback to inflammatory gene expression was detected in atherosclerotic patients. Transcriptome differences of circulating cells possibly play less of a role than hitherto thought in the individual patient''s susceptibility to atherosclerotic CAD, when appropriately matched for clinical symptoms and medication taken. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
46. Interferon-β Signaling Is Enhanced in Patients With Insufficient Coronary Collateral Artery Development and Inhibits Arteriogenesis in Mice.
- Author
-
Schirmer, Stephan H., Fledderus, Joost O., Bot, Pieter T. G., Moerland, Perry D., Hoefer, Imo E., Baan Jr., Jan, Henriques, José P. S., van der Schaaf, René J., Vis, Marije M., Horrevoets, Anton J. G., Piek, Jan J., and van Royen, Niels
- Subjects
MEDICAL genetics ,ARTERIAL diseases ,BLOOD flow ,MONOCYTES ,INTERFERONS ,CORONARY arteries ,PATIENTS - Abstract
The article offers information on research concerning the stimulation of collateral artery growth factor and its effect on patients with single-vessel coronary artery disease. It cites that patients with differing arteriogenic response as measured with collateral flow index display differential transcriptomes of stimulated monocytes. Moreover, it found that Interferon (IFN)-β inhibited smooth muscle cell proliferation in vitro and hampers arteriogenesis in mice.
- Published
- 2008
- Full Text
- View/download PDF
47. Anti-tumor necrosis factor-α therapies attenuate adaptive arteriogenesis in the rabbit.
- Author
-
Grundmann, Sebastian, Hoefer, Imo, Ulusans, Susann, van Royen, Niels, Schirmer, Stephan H., Ozaki, C. Keith, Bode, Christoph, Piek, Jan J., and Buschmann, Ivo
- Subjects
ANTIRHEUMATIC agents ,INFLIXIMAB ,ETANERCEPT ,TUMOR necrosis factors ,ARTERIAL diseases ,CARDIOVASCULAR system ,LABORATORY rabbits - Abstract
The specific antagonists of tumor necrosis factor-α (TNF-α), infliximab and etanercept, are established therapeutic agents for inflammatory diseases such as rheumatoid arthritis and Crohn's disease. Although the importance of TNF-α in chronic inflammatory diseases is well established, little is known about its implications in the cardiovascular system. Because proliferation of arteriolar connections toward functional collateral arteries (arteriogenesis) is an inflammatory-like process, we tested in vivo the hypothesis that infliximab and etanercept have antiarteriogenic actions. Sixty-three New Zealand White rabbits underwent femoral artery occlusion and received infliximab, etanercept, or vehicle according to clinical dosage regimes. After 1 wk, collateral conductance, assessed with fluorescent microspheres, revealed significant inhibition of arteriogenesis (collateral conductance): 52.4 (SD 8.1), 35.2 (SD 7.7), and 33.3 (SD 10.1) ml·min
-1 100 mmHg-1 with PBS, infliximab, and etanercept, respectively (P < 0.001). High-resolution angiography showed no significant differences in number of collateral arteries, but immunohistochemical analysis demonstrated a decrease in mean collateral diameter, proliferation of vascular smooth muscle cells, and reduction of leukocyte accumulation around collateral arteries in treated groups. Infliximab and etanercept bound to infiltrating leukocytes, which are important mediators of arteriogenesis. Infliximab induced monocyte apoptosis, and neither substance affected monocyte expression of the adhesion molecule Mac-1. We demonstrated that TNF-α serves as a pivotal modulator of arteriogenesis, which is attenuated by treatment with TNF-α inhibitors. Reduction of collateral conductance is most likely due to inhibition of perivascular leukocyte infiltration and subsequent lower vascular smooth muscle cell proliferation. This is the first report showing a negative influence of TNF-α inhibitors on collateral artery growth. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
48. Differential effects of MCP-1 and leptin on collateral flow and arteriogenesis
- Author
-
Schirmer, Stephan H., Buschmann, Ivo R., Jost, Marco M., Hoefer, Imo E., Grundmann, Sebastian, Andert, Jan-Philip, Ulusans, Susann, Bode, Christoph, Piek, Jan J., and van Royen, Niels
- Subjects
- *
LEPTIN , *HORMONES , *BLOOD vessels , *MUSCLE cells - Abstract
Strategies to therapeutically stimulate collateral artery growth in experimental models have been studied intensively in the last decades. However, the experimental methods to detect collateral artery growth are discussed controversially and vary significantly. We compared different methods in a model of arteriogenesis in the rabbit hind limb and determined the effects on collateral flow of a known pro-arteriogenic factor, monocyte chemoattractant protein-1 (MCP-1), and a cytokine not previously evaluated for its arteriogenic efficacy, the adipocytokine leptin.Forty-two New Zealand White rabbits received either MCP-1, leptin or PBS after ligation of the right femoral artery. The pro-arteriogenic effect of MCP-1 was confirmed by flow measurements during reactive hyperemia, as demonstrated by increased flow ratio (PBS 0.56±0.07 vs. MCP-1 0.77±0.06, no unit, p<0.0001), ankle-brachial index and microsphere-based conductance measurements (PBS 50.8±2.1 vs. MCP-1 225.8±8.8 ml/min/100 mm Hg, p<0.001). Biological activity of leptin on rabbit monocytes was shown by a dose dependent increase in Mac-1 expression. In-vivo administration of leptin also led to an increase in hyperemic flow and flow ratio (leptin 0.69±0.03, p<0.05 vs. PBS), but not to an increase in collateral conductance (leptin 54.7±4.1 ml/min/100 mm Hg, p=ns vs. PBS) or proliferation of vascular smooth muscle cells (Ki-67 staining: PBS 24.7±3.9%, leptin 22.7%±0.8% (p=ns), MCP-1 32.0±1.9% (p<0.01)). Ki-67 mRNA measured by real-time polymerase chain reaction increased (8.8±3.1-fold, p<0.01) during natural arteriogenesis, and was further enhanced (25.5±8.1-fold, p<0.005) after stimulation with MCP-1.MCP-1 and leptin increase collateral flow in the rabbit hind limb model. In contrast to MCP-1, leptin does not enhance direct markers of vascular proliferation such as collateral conductance under maximal vasodilation and proliferation indices. The observed increase in hyperemic collateral flow thus most probably can be attributed to the well-documented vasodilatory effects of leptin. These data stress the necessity of the use of proliferation markers and microsphere-based conductance measurements under maximal vasodilation in order to separate effects of substances on vascular proliferation from effects on vasodilation. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
49. Design of the START-trial: STimulation of ARTeriogenesis using subcutaneous application of GM-CSF as a new treatment for peripheral vascular disease. A randomized, double-blind, placebo-controlled trial.
- Author
-
van Royen, Niels, Piek, Jan J., Legemate, Dink A., Schaper, Wolfgang, Oskam, Jacques, Atasever, Bektas, Voskuil, Michiel, Ubbink, Dirk, Schirmer, Stephan H., Buschmann, Ivo, Bode, Christoph, and Buschmann, Eva E.
- Subjects
PERIPHERAL vascular diseases ,ANGIOPLASTY ,NEOVASCULARIZATION ,MONOCYTES ,PLACEBOS ,BLOOD circulation ,GROWTH factors - Abstract
Peripheral arterial disease (PAD) affects a large percentage of the elderly population. Standard invasive treatment, apart from risk factor modulation, consists of bypass surgery or percutaneous transluminal angioplasty. However, symptomatic recurrence rates are high for both procedures and a substantial part of the patient population with PAD is not a candidate for invasive revascularization due to complexity of the lesion and/or co-morbidity. Therapeutic arteriogenesis has been proposed as an alternative treatment option. The present paper describes the design of the START-trial. This trial aims to determine the potential of the proarteriogenic substance granulocyte/macrophage colony stimulating factor (GM-CSF) to increase maximal walking distance in patients with intermittent claudication. A double-blinded, randomized, placebo-controlled study will be performed in 40 patients with peripheral obstructive arterial disease Rutherford grade I, category 2 or 3, that are candidates for bypass surgery or percutaneous transluminal angioplasty. Based on pharmacokinetic and toxicologic studies, a dose of 10 μg/kg will be used. Patients will be treated for a period of 14 days on each consecutive day, with the last injection applied on day 12. The primary endpoint will be the change in walking distance from day 0 to day 14 as assessed by an exercise treadmill test. Secondary endpoints will be the ankle–brachial index at rest and after exercise, the pain-free walking distance and cutaneous microcirculatory alterations as assessed by laser Doppler fluxmetry. Iliac flow reserve and conductance will be measured by magnetic resonance imaging. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
50. Primum non nocere: the dangers of deferring heart failure therapy.
- Author
-
Böhm, Michael, Laufs, Ulrich, Mahfoud, Felix, Schirmer, Stephan H., and Kindermann, Ingrid
- Subjects
CHRONIC diseases ,HEART failure ,INFORMED consent (Medical law) ,PAMPHLETS ,TREATMENT delay (Medicine) ,DISEASE complications - Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.